When compared to GLP1RAs, which improve insulin sensitivity primarily through weight reduction, a post-doc regression analysis of HOMA2-IR indicates that only 2030% of the improvement in insulin sensitization observed with tirzepatide is due to weight loss (NCT03951753) [77, 78]
Diabetes Obes Metab 25:317 Eid A, Mhatre I, Richardson JR (2019) Gene-environment interactions in Alzheimers disease: A potential path to precision medicine
Your dose will be adjusted as treatment continues
Most patients begin experiencing noticeable weight reduction within the first 4-8 weeks of treatment, with progressive weight loss continuing over 6-12 months as the dose is titrated upward
3 Tirzepatide may have a moderately higher risk of severe gastrointestinal adverse events compared with GLP-1 receptor agonists
Individual preference and consistency matter most